SEOM-TTCC clinical guideline in nasopharynx cancer (2021)

• Antonio Rueda Domínguez ^[6] ; Beatriz Cirauqui ^[7] ; Almudena García Castaño ^[8] ; Ruth Alvarez Cabellos ^[1] ; Alberto Carral Maseda ^[2] ; Beatriz Castelo Fernández ^[9] ; Leticia Iglesias Rey ^[3] ; Jordi Rubió-Casadevall ^[4] ; Virginia Arrazubi ^[5] ; Ricard Mesía ^[7]
  1. [1] Hospital Virgen de la Salud

     Hospital Virgen de la Salud

     Toledo, España

     
  2. [2] Hospital Universitario Lucus Augusti

     Hospital Universitario Lucus Augusti

     Lugo, España

     
  3. [3] Complexo Hospitalario Universitario de Ourense

     Complexo Hospitalario Universitario de Ourense

     Ourense, España

     
  4. [4] Institute Catalá Oncología

     Institute Catalá Oncología

     Barcelona, España

     
  5. [5] Instituto de Investigación Sanitaria de Navarra

     Instituto de Investigación Sanitaria de Navarra

     Pamplona, España

     
  6. [6] Medical Oncology Intercenter Unit, Regional and Virgen de La Victoria University Hospitals, IBIMA, 29010, Málaga, Spain
  7. [7] Medical Oncology Department. Catalan Institut of Oncology - Badalona. B-ARGO Group, IGTP, Badalona, Spain
  8. [8] Medical Oncology Service, Hospital Marqués de Valdecilla, Santander, Spain
  9. [9] Medical Oncology Department, Hospital Universitario de La Paz, Madrid, Spain

  Mostrar afiliaciones +
• Localización: Clinical & translational oncology, ISSN 1699-048X, Vol. 24, Nº. 4 (April), 2022, págs. 670-680
• Idioma: inglés
• Enlaces
  • Texto completo (pdf)
• Resumen

  • Nasopharyngeal carcinoma (NPC) is distinct from other cancers of the head and neck in biology, epidemiology, histology, natural history, and response to treatment. Radiotherapy (RT) is the cornerstone of locoregional treatment of non-disseminated disease and the association of chemotherapy improves the rates of survival. In the case of metastatic disease stages, treatment requires platinum/gemcitabine-based chemotherapy and patients may achieve a long survival time.